CL
SGNT

Croft-Leominster’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Croft-Leominster’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,500
Closed -$278K – 195
2015
Q4 		$278K Buy
17,500
+6,000
+52% +$94.5K 0.06% 142
2015
Q3 		$176K Buy
+11,500
New +$249K 0.04% 160

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Croft-Leominster's SGNT Position: Q1 2016 in Review

Croft-Leominster sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q1 2016, closing a stake of 17,500 shares — an estimated $278K sold.

Croft-Leominster first reported a position in SGNT in Q3 2015 and held it in 2 quarters. The position peaked at $278K in Q4 2015. 136 funds tracked by Wall St. Rank hold SGNT as of Q1 2016.

  • Croft-Leominster reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q1 2016 after selling out during the quarter.
  • Croft-Leominster sold 17,500 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q1 2016, an estimated $278K.
  • Croft-Leominster first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2015 and held it in 2 quarters.
  • Croft-Leominster's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $278K in Q4 2015.
  • 136 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q1 2016.

Based on Croft-Leominster's 13F filing for Q1 2016, filed 16 May 2016.